Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells.

Kim Y, Maciag AE, Cao Z, Deschamps JR, Saavedra JE, Keefer LK, Holland RJ.

Bioorg Med Chem. 2015 Aug 1;23(15):4980-8. doi: 10.1016/j.bmc.2015.05.020. Epub 2015 May 19.

PMID:
26043946
2.

Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells.

Maciag AE, Holland RJ, Kim Y, Kumari V, Luthers CE, Sehareen WS, Biswas D, Morris NL, Ji X, Anderson LM, Saavedra JE, Keefer LK.

J Med Chem. 2014 Mar 27;57(6):2292-302. doi: 10.1021/jm401550d. Epub 2014 Feb 25.

3.

Co-transcriptional production of RNA-DNA hybrids for simultaneous release of multiple split functionalities.

Afonin KA, Desai R, Viard M, Kireeva ML, Bindewald E, Case CL, Maciag AE, Kasprzak WK, Kim T, Sappe A, Stepler M, Kewalramani VN, Kashlev M, Blumenthal R, Shapiro BA.

Nucleic Acids Res. 2014 Feb;42(3):2085-97. doi: 10.1093/nar/gkt1001. Epub 2013 Nov 4.

4.

Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.

Maciag AE, Holland RJ, Robert Cheng YS, Rodriguez LG, Saavedra JE, Anderson LM, Keefer LK.

Redox Biol. 2013 Feb 1;1:115-24. doi: 10.1016/j.redox.2012.12.002. eCollection 2013.

5.

Activation of different split functionalities on re-association of RNA-DNA hybrids.

Afonin KA, Viard M, Martins AN, Lockett SJ, Maciag AE, Freed EO, Heldman E, Jaeger L, Blumenthal R, Shapiro BA.

Nat Nanotechnol. 2013 Apr;8(4):296-304. doi: 10.1038/nnano.2013.44. Epub 2013 Mar 31.

6.

Cross-linking protein glutathionylation mediated by O2-arylated bis-diazeniumdiolate "Double JS-K".

Holland RJ, Maciag AE, Kumar V, Shi L, Saavedra JE, Prud'homme RK, Chakrapani H, Keefer LK.

Chem Res Toxicol. 2012 Dec 17;25(12):2670-7. doi: 10.1021/tx3003142. Epub 2012 Nov 9.

7.

Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.

Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2012 May 1;20(9):3094-9. doi: 10.1016/j.bmc.2012.02.045. Epub 2012 Mar 9.

8.

Diazeniumdiolated carbamates: a novel class of nitric oxide donors.

Nandurdikar RS, Maciag AE, Cao Z, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2012 Mar 15;20(6):2025-9. doi: 10.1016/j.bmc.2012.01.046. Epub 2012 Feb 4.

9.

Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class.

Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer LK.

For Immunopathol Dis Therap. 2012;3(2):91-95.

10.

Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE.

J Med Chem. 2011 Nov 24;54(22):7751-8. doi: 10.1021/jm2004128. Epub 2011 Oct 28.

11.

The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline.

Hong SY, Borchert GL, Maciag AE, Nandurdikar RS, Saavedra JE, Keefer LK, Phang JM, Chakrapani H.

ACS Med Chem Lett. 2010 Nov 11;1(8):386-389.

12.

The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK.

J Pharmacol Exp Ther. 2011 Feb;336(2):313-20. doi: 10.1124/jpet.110.174904. Epub 2010 Oct 20.

13.

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH.

J Exp Med. 2010 Oct 25;207(11):2455-67. doi: 10.1084/jem.20100670. Epub 2010 Oct 4.

14.

"Click" reaction in conjunction with diazeniumdiolate chemistry: developing high-load nitric oxide donors.

Oladeinde OA, Hong SY, Holland RJ, Maciag AE, Keefer LK, Saavedra JE, Nandurdikar RS.

Org Lett. 2010 Oct 1;12(19):4256-9. doi: 10.1021/ol101645k.

15.

Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Kumar V, Hong SY, Maciag AE, Saavedra JE, Adamson DH, Prud'homme RK, Keefer LK, Chakrapani H.

Mol Pharm. 2010 Feb 1;7(1):291-8. doi: 10.1021/mp900245h.

16.

Glycosylated PROLI/NO derivatives as nitric oxide prodrugs.

Nandurdikar RS, Maciag AE, Hong SY, Chakrapani H, Citro ML, Keefer LK, Saavedra JE.

Org Lett. 2010 Jan 1;12(1):56-9. doi: 10.1021/ol902481s.

17.

The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.

Maciag AE, Saavedra JE, Chakrapani H.

Anticancer Agents Med Chem. 2009 Sep;9(7):798-803. Epub 2009 Sep 1. Review.

PMID:
19538173
18.

Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.

Nandurdikar RS, Maciag AE, Citro ML, Shami PJ, Keefer LK, Saavedra JE, Chakrapani H.

Bioorg Med Chem Lett. 2009 May 15;19(10):2760-2. doi: 10.1016/j.bmcl.2009.03.115. Epub 2009 Mar 28.

19.

JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).

Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer LK.

Leuk Res. 2009 Nov;33(11):1525-9. doi: 10.1016/j.leukres.2009.01.002. Epub 2009 Feb 3.

20.

Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Andrei D, Maciag AE, Chakrapani H, Citro ML, Keefer LK, Saavedra JE.

J Med Chem. 2008 Dec 25;51(24):7944-52. doi: 10.1021/jm800831y.

21.

Cell-permeable esters of diazeniumdiolate-based nitric oxide prodrugs.

Chakrapani H, Maciag AE, Citro ML, Keefer LK, Saavedra JE.

Org Lett. 2008 Nov 20;10(22):5155-8. doi: 10.1021/ol8020989. Epub 2008 Oct 29.

PMID:
18956868
22.

Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

Chakrapani H, Kalathur RC, Maciag AE, Citro ML, Ji X, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2008 Nov 15;16(22):9764-71. doi: 10.1016/j.bmc.2008.09.063. Epub 2008 Sep 30.

Supplemental Content

Loading ...
Support Center